MARIPOSA：Amivantamab + Lazertinib 一线对比奥希替尼

类型: 论文 发表日期: 2024-06-26 入库日期: 2026-05-21 来源: PubMed / FDA 标签: EGFR L858R, Amivantamab, Lazertinib, MARIPOSA, 一线治疗, 高风险

Citation

Cho BC, Lu S, Felip E, et al. Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC. PubMed: 38924756

FDA snapshot: Drug Trials Snapshot - LAZCLUZE

Why this is in CCL

Mom is not treatment-naive anymore, but MARIPOSA helps define the modern EGFR L858R first-line landscape and may matter when doctors discuss “what would be used today” or sequence-related implications after osimertinib.

Key takeaways

• Population: untreated locally advanced/metastatic NSCLC with EGFR exon 19 deletion or L858R.
• FDA snapshot reports median PFS 23.7 months for lazertinib + amivantamab vs 16.6 months for osimertinib; HR 0.70.
• Major added burden: rash, nail toxicity, infusion-related reaction, edema, and thromboembolic precautions.

Practical relevance

• Useful comparator for high-risk biology, especially L858R with TP53/RB1 co-alterations.
• May shape later-line access or physician thinking about EGFR/MET bispecific antibody strategies.
• Not a direct “switch now” argument by itself because mom has already had prolonged osimertinib/chemotherapy exposure.